OPTN vs. SCPH, VERU, CHMA, AQST, XERS, APLT, OCS, IGMS, AVTE, and MREO
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include scPharmaceuticals (SCPH), Veru (VERU), Chiasma (CHMA), Aquestive Therapeutics (AQST), Xeris Biopharma (XERS), Applied Therapeutics (APLT), Oculis (OCS), IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), and Mereo BioPharma Group (MREO). These companies are all part of the "medical" sector.
OptiNose (NASDAQ:OPTN) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
OptiNose currently has a consensus target price of $3.67, suggesting a potential upside of 245.91%. scPharmaceuticals has a consensus target price of $19.00, suggesting a potential upside of 406.67%. Given scPharmaceuticals' higher possible upside, analysts plainly believe scPharmaceuticals is more favorable than OptiNose.
OptiNose has a net margin of -41.55% compared to scPharmaceuticals' net margin of -327.29%. OptiNose's return on equity of 0.00% beat scPharmaceuticals' return on equity.
OptiNose received 88 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.24% of users gave scPharmaceuticals an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
OptiNose has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500.
85.6% of OptiNose shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 2.7% of OptiNose shares are held by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
OptiNose has higher revenue and earnings than scPharmaceuticals. OptiNose is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, OptiNose had 2 more articles in the media than scPharmaceuticals. MarketBeat recorded 2 mentions for OptiNose and 0 mentions for scPharmaceuticals. OptiNose's average media sentiment score of 1.83 beat scPharmaceuticals' score of 0.00 indicating that OptiNose is being referred to more favorably in the media.
Summary
OptiNose beats scPharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
